This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

The Department of Ophthalmology’s annual Buffalo Ophthalmology Symposium at the Jacobs School of Medicine and Biomedical Sciences featured both a glance back at the department’s history and an eye to ...

Patients had a small but nonsignificant survival advantage when continuing with anti-VEGF therapy in the second-line instead ...

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Obesity caused by a high-fat Western diet damages the pancreas, affecting insulin production and blood sugar control even ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: ...

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 ...